$PLRX
PLIANT THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000174647324000171 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.26M
YoY Change -7.1%
% of Gross Profit
Research & Development $47.75M
YoY Change 47.67%
% of Gross Profit
Depreciation & Amortization $500.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $62.01M
YoY Change 30.05%
Operating Profit -$62.01M
YoY Change 30.05%
Interest Expense $4.251M
YoY Change 1241.01%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$57.76M
YoY Change 39.22%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$57.76M
YoY Change 39.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.95
Diluted Earnings Per Share -$0.95
COMMON SHARES
Basic Shares Outstanding 60.85M shares 60.80M shares
Diluted Shares Outstanding 60.73M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $404.5M
YoY Change -22.74%
Cash & Equivalents $79.62M
Short-Term Investments $324.9M
Other Short-Term Assets $3.301M
YoY Change -61.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $410.0M
YoY Change -23.26%
LONG-TERM ASSETS
Property, Plant & Equipment $5.671M
YoY Change 42.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $427.0K
YoY Change 8.93%
Total Long-Term Assets $35.63M
YoY Change 481.4%
TOTAL ASSETS
Total Short-Term Assets $410.0M
Total Long-Term Assets $35.63M
Total Assets $445.7M
YoY Change -17.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.890M
YoY Change 105.06%
Accrued Expenses $9.715M
YoY Change 16.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.95M
YoY Change 45.84%
LONG-TERM LIABILITIES
Long-Term Debt $30.14M
YoY Change 201.39%
Other Long-Term Liabilities $29.75M
YoY Change
Total Long-Term Liabilities $59.89M
YoY Change 498.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.95M
Total Long-Term Liabilities $59.89M
Total Liabilities $99.84M
YoY Change 166.85%
SHAREHOLDERS EQUITY
Retained Earnings -$660.3M
YoY Change 43.97%
Common Stock $1.005B
YoY Change 4.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.8M
YoY Change
Total Liabilities & Shareholders Equity $445.7M
YoY Change -17.54%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$57.76M
YoY Change 39.23%
Depreciation, Depletion And Amortization $500.0K
YoY Change 0.0%
Cash From Operating Activities -$32.27M
YoY Change -10.9%
INVESTING ACTIVITIES
Capital Expenditures $896.0K
YoY Change 895.56%
Acquisitions
YoY Change
Other Investing Activities $31.86M
YoY Change -16.93%
Cash From Investing Activities $30.96M
YoY Change -19.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 543.0K
YoY Change -22.43%
NET CHANGE
Cash From Operating Activities -32.27M
Cash From Investing Activities 30.96M
Cash From Financing Activities 543.0K
Net Change In Cash -770.0K
YoY Change -128.1%
FREE CASH FLOW
Cash From Operating Activities -$32.27M
Capital Expenditures $896.0K
Free Cash Flow -$33.17M
YoY Change -8.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001746473
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Address Line1
EntityAddressAddressLine1
331 Oyster Point Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
481-6770
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79616000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63234000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
324897000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
431011000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.66
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60730935 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60730935 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-57763000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1465000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56298000 usd
dei Entity File Number
EntityFileNumber
001-39303
dei Entity Registrant Name
EntityRegistrantName
PLIANT THERAPEUTICS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4272481
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57679000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59688451 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60432643 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60432643 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58319608 shares
us-gaap Net Income Loss
NetIncomeLoss
-160572000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1465000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
334000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9666000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-834000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
477000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5518000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
410031000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
505502000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5671000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39952000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28524000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29752000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
30139000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10054000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
99843000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
38578000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59921002 shares
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
972973000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-660320000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-499748000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
848000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
345000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
345822000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
473576000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
445665000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512154000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1580000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47754000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32339000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130517000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94614000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14260000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15346000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44528000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44074000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
62014000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
47685000 usd
us-gaap Operating Expenses
OperatingExpenses
138688000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-62014000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47685000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-137108000 usd
CY2024Q3 plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
5128000 usd
CY2023Q3 plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
6515000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
877000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
317000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2190000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
946000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
3661000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11923000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
627000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37548000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
561920000 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60853623 shares
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11257000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3567000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28054000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1211000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1482000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1482000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000 usd
CY2024Q3 us-gaap Assets
Assets
445665000 usd
CY2023Q4 us-gaap Assets
Assets
512154000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6890000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4531000 usd
CY2024Q3 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
23025000 usd
CY2023Q4 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
12456000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9715000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10219000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
322000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1318000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60849503 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60849503 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59921002 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1005288000 usd
us-gaap Operating Expenses
OperatingExpenses
175045000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-175045000 usd
plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
16663000 usd
plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
17827000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-57763000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
us-gaap Net Income Loss
NetIncomeLoss
-160572000 usd
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59688451 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58319608 shares
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
334000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
503000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
51000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
503000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
51000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41153000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160069000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-120176000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
473576000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1879000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-46955000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
437332000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
684000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10644000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-128000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-55854000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
392678000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
543000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8899000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1465000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-57763000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
345822000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
313342000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
269915000 usd
CY2023Q2 plrx Adjustments To Additional Paid In Capital Public Offering Expenses
AdjustmentsToAdditionalPaidInCapitalPublicOfferingExpenses
133000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
334000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13046000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-910000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-41192000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
533065000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
774000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10362000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
334000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
503048000 usd
us-gaap Net Income Loss
NetIncomeLoss
-160572000 usd
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
us-gaap Depreciation
Depreciation
1667000 usd
us-gaap Depreciation
Depreciation
1377000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
29209000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35331000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2640000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1833000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1945000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
10215000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1983000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5739000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3583000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
35000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-367000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2358000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1797000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9935000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2082000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-727000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2004000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107841000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91259000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
177930000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
525572000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
282777000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
367499000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3639000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
860000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
101208000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158933000 usd
plrx Proceeds From Issuances Of Common Stock Under Benefit Plans
ProceedsFromIssuancesOfCommonStockUnderBenefitPlans
3106000 usd
plrx Proceeds From Issuances Of Common Stock Under Benefit Plans
ProceedsFromIssuancesOfCommonStockUnderBenefitPlans
4769000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
19909000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
0 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
834000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
270251000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23015000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
274186000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16382000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23994000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64716000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33685000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81098000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57679000 usd
us-gaap Interest Paid Net
InterestPaidNet
1850000 usd
us-gaap Interest Paid Net
InterestPaidNet
864000 usd
CY2024Q3 plrx Cash And Cash Equivalents At Carrying Value Rounded
CashAndCashEquivalentsAtCarryingValueRounded
79616000 usd
CY2023Q3 plrx Cash And Cash Equivalents At Carrying Value Rounded
CashAndCashEquivalentsAtCarryingValueRounded
57679000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
1482000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81098000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
503000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
51000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
132000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29779000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, stock-based compensation expense, operating lease right-of-use (“ROU”) assets and liabilities, accruals and prepayments for research and development costs, income taxes and uncertain tax positions. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
382686000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
888000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
383534000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
487907000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
822000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
477000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
488252000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
382686000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
888000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
383534000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
487907000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
822000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
488252000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16019000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12249000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10348000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8682000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5671000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3567000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
500000 usd
us-gaap Depreciation
Depreciation
1700000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
500000 usd
us-gaap Depreciation
Depreciation
1400000 usd
CY2024Q3 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1823000 usd
CY2023Q4 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
3403000 usd
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
2217000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
2997000 usd
CY2024Q3 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
762000 usd
CY2023Q4 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
2454000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
31000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1131000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
685000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1272000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5518000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11257000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8423000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9042000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1292000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1177000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9715000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10219000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000000 usd
CY2024Q3 plrx Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
0 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2024Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
174000 usd
CY2024Q3 plrx Long Term Debt Accretion Of Final Payment
LongTermDebtAccretionOfFinalPayment
313000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
30139000 usd
CY2024Q3 plrx Number Of Classes Of Stock Authorized
NumberOfClassesOfStockAuthorized
2 class
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 plrx Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1 vote
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15211747 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12544982 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8899000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10363000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29209000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35331000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 plrx Valuation Allowance As Percentage On Deferred Tax Assets
ValuationAllowanceAsPercentageOnDeferredTaxAssets
1
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
plrx Contractual Arrangements Cancellation Period
ContractualArrangementsCancellationPeriod
P30D
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
527000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3548000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4406000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5898000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7468000 usd
CY2024Q3 plrx Lessee Operating Lease Liability To Be Paid Year Five And After Year Five
LesseeOperatingLeaseLiabilityToBePaidYearFiveAndAfterYearFive
20822000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
42669000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12595000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
322000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29752000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.093
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.133
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1531000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
698000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
4252000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2142000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
480000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
130000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
917000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
620000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
2011000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
828000 usd
us-gaap Lease Cost
LeaseCost
5169000 usd
us-gaap Lease Cost
LeaseCost
2762000 usd
CY2024Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000 usd
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9206448 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7769360 shares
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001746473-24-000171-index-headers.html Edgar Link pending
0001746473-24-000171-index.html Edgar Link pending
0001746473-24-000171.txt Edgar Link pending
0001746473-24-000171-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plrx-20240930.htm Edgar Link pending
plrx-20240930.xsd Edgar Link pending
plrx-20240930xex311.htm Edgar Link pending
plrx-20240930xex312.htm Edgar Link pending
plrx-20240930xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
plrx-20240930_cal.xml Edgar Link unprocessable
plrx-20240930_def.xml Edgar Link unprocessable
plrx-20240930_lab.xml Edgar Link unprocessable
plrx-20240930_pre.xml Edgar Link unprocessable
plrx-20240930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable